1. Yokoyama N, Maeda K, Mikami T. Recombinant viral vector vaccines for the veterinary use. J Vet Med Sci. 1997; 59:311–322.
2. Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. Viruses. 2014; 6:2531–2550.
3. Duan Z, Xu H, Ji X, Zhao J. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases. Future Microbiol. 2015; 10:1307–1323.
4. Hines NL, Miller CL. Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics. Vet Med Int. 2012; 2012:708216.
5. Dortmans JC, Peeters BP, Koch G. Newcastle disease virus outbreaks: vaccine mismatch or inadequate application? Vet Microbiol. 2012; 160:17–22.
6. Tayeb S, Zakay-Rones Z, Panet A. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother. 2015; 4:49–62.
7. Miller PJ, Decanini EL, Afonso CL. Newcastle disease: evolution of genotypes and the related diagnostic challenges. Infect Genet Evol. 2010; 10:26–35.
8. Kim SH, Samal SK. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses. 2016; 8:E183.
9. Ganar K, Das M, Sinha S, Kumar S. Newcastle disease virus: current status and our understanding. Virus Res. 2014; 184:71–81.
10. Peeters BP, Gruijthuijsen YK, de Leeuw OS, Gielkens AL. Genome replication of Newcastle disease virus: involvement of the rule-of-six. Arch Virol. 2000; 145:1829–1845.
11. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol. 2003; 77:9522–9532.
12. Huang Z, Elankumaran S, Panda A, Samal SK. Recombinant Newcastle disease virus as a vaccine vector. Poult Sci. 2003; 82:899–906.
13. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999; 73:5001–5009.
14. Romer-Oberdorfer A, Mundt E, Mebatsion T, Buchholz UJ, Mettenleiter TC. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol. 1999; 80(Pt 11):2987–2995.
15. Huang Z, Krishnamurthy S, Panda A, Samal SK. High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J Gen Virol. 2001; 82(Pt 7):1729–1736.
16. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, Garcia-Sastre A. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol. 2009; 83:584–597.
17. Zhao W, Zhang Z, Zsak L, Yu Q. P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. J Gen Virol. 2015; 96(Pt 1):40–45.
18. Samal SK. Newcastle disease and related avian paramyxoviruses. In : Samal SK, editor. The biology of paramyxoviruses. Norfolk: Caister Academic Press;2011. p. 69–114.
19. Khattar SK, Collins PL, Samal SK. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010; 28:3159–3170.
20. Zhang M, Ge J, Wen Z, et al. Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus. Arch Virol. 2017; 162:359–367.
21. Kortekaas J, Dekker A, de Boer SM, et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine. 2010; 28:2271–2276.
22. Zhang M, Ge J, Li X, et al. Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice. Virol J. 2016; 13:31.
23. Ge J, Wang X, Tian M, et al. Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks. Vaccine. 2015; 33:2457–2462.
24. Ge J, Wang X, Tao L, et al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol. 2011; 85:8241–8252.
25. Kong D, Wen Z, Su H, et al. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology. 2012; 432:327–335.
26. Wang J, Yang J, Ge J, et al. Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry. Virol J. 2016; 13:109.
27. Samy AM, Peterson AT, Hall M. Phylogeography of Rift Valley fever virus in Africa and the Arabian peninsula. PLoS Negl Trop Dis. 2017; 11:e0005226.
28. Botros B, Omar A, Elian K, et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006; 78:787–791.
29. Kamal SA. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J. 2009; 6:94.
30. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol. 2005; 292:45–56.
31. World Health Organization. WHO expert consultation on rabies. First report. WHO Technical Report Series 931. Geneva: World Health Organization;2005.
32. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, García-Sastre A. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol. 2009; 83:584–597.
33. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol. 2011; 85:10529–10541.
34. Khattar SK, Manoharan V, Bhattarai B, LaBranche CC, Montefiori DC, Samal SK. Mucosal immunization with Newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus Env and Gag challenges. MBio. 2015; 6:e01005.
35. Nakaya T, Cros J, Park MS, et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001; 75:11868–11873.
36. DiNapoli JM, Yang L, Suguitan A Jr, et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol. 2007; 81:11560–11568.
37. DiNapoli JM, Kotelkin A, Yang L, et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A. 2007; 104:9788–9793.
38. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine. 2010; 29:17–25.
39. Kim SH, Chen S, Jiang X, Green KY, Samal SK. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J Virol. 2014; 88:9718–9727.
40. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol. 2006; 80:1130–1139.
41. Bukreyev A, Huang Z, Yang L, et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. 2005; 79:13275–13284.
42. Swayne DE, Spackman E, Pantin-Jackwood M. Success factors for avian influenza vaccine use in poultry and potential impact at the wild bird-agricultural interface. Ecohealth. 2014; 11:94–108.
43. Peyre M, Fusheng G, Desvaux S, Roger F. Avian influenza vaccines: a practical review in relation to their application in the field with a focus on the Asian experience. Epidemiol Infect. 2009; 137:1–21.
44. Chen H. H5N1 avian influenza vaccination in China. In : OIE Regional Workshop on Enhancing Influenza A Viruses National Surveillance; 2014 Aug 26-28; Tokyo, Japan.
45. Ge J, Deng G, Wen Z, et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol. 2007; 81:150–158.
46. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A. 2006; 103:8203–8208.
47. Chen HY, Shang YH, Yao HX, et al. Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing HA of H9N2 avain influenza virus and chicken IL-18. Antiviral Res. 2011; 91:50–56.
48. Li C, Bu Z, Chen H. Avian influenza vaccines against H5N1 ‘bird flu’. Trends Biotechnol. 2014; 32:147–156.
49. Suarez DL, Pantin-Jackwood MJ. Recombinant viral-vectored vaccines for the control of avian influenza in poultry. Vet Microbiol. 2016; 11. 24. [Epub]. DOI:
10.1016/j.vetmic.2016.11.025.
50. Nayak B, Rout SN, Kumar S, et al. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One. 2009; 4:e6509.
51. Steglich C, Grund C, Ramp K, et al. Chimeric newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity. PLoS One. 2013; 8:e72530.
52. Huang Z, Elankumaran S, Yunus AS, Samal SK. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol. 2004; 78:10054–10063.
53. Toro H, Zhao W, Breedlove C, Zhang Z, Yu Q, Van Santen V. Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge. Avian Dis. 2014; 58:83–89.
54. Kanabagatte Basavarajappa M, Kumar S, Khattar SK, Gebreluul GT, Paldurai A, Samal SK. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens. Vaccine. 2014; 32:3555–3563.
55. Zhao W, Spatz S, Zhang Z, et al. Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J Virol. 2014; 88:8397–8406.
56. Kim SH, Paldurai A, Samal SK. A novel chimeric Newcastle disease virus vectored vaccine against highly pathogenic avian influenza virus. Virology. 2017; 503:31–36.
57. Hu H, Roth JP, Estevez CN, Zsak L, Liu B, Yu Q. Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys. Vaccine. 2011; 29:8624–8633.
58. Guy JS, Barnes HJ, Smith L. Increased virulence of modified-live infectious laryngotracheitis vaccine virus following bird-to-bird passage. Avian Dis. 1991; 35:348–355.
59. Hughes CS, Williams RA, Gaskell RM, et al. Latency and reactivation of infectious laryngotracheitis vaccine virus. Arch Virol. 1991; 121:213–218.